CO63 Comparative Clinical Effectiveness of Monoclonal Antibodies for the Treatment of Relapsing Multiple Sclerosis: A Systematic Review and Network Meta-Analysis
To evaluate the relative clinical effectiveness of five monoclonal antibodies (natalizumab, ofatumumab, ocrelizumab, rituximab, ublituximab) as first-line disease-modifying therapies (DMT) for relapsing forms of multiple sclerosis (MS); and to compare these treatments to placebo and oral DMTs (dimethyl fumarate, fingolimod, ozanimod, ponesimod, and teriflunomide). (Source: Value in Health)
Source: Value in Health - June 1, 2023 Category: International Medicine & Public Health Authors: D. Nikitin, G. Lin, A. McKenna, S. Herron-Smith, J. Campbell, F.O. Agboola Source Type: research
CO39 Real-World Assessment of Efficacy and Safety of Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: Systematic Review and Meta-Analysis
The efficacy and safety of natalizumab versus fingolimod for relapsing-remitting multiple sclerosis (RRMS) had conflicting results, according to data from various medical centers across the globe. Therefore, we performed a systematic review and meta-analysis of data from real-world evidence (RWE) studies to evaluate the efficacy and safety Parameters of Natalizumab Versus Fingolimod. (Source: Value in Health)
Source: Value in Health - June 1, 2023 Category: International Medicine & Public Health Authors: Z. Almalki Source Type: research
Treatments of paediatric multiple sclerosis: Efficacy and tolerance in a longitudinal follow-up study
CONCLUSION: In this real-world setting, newer DMTs showed better efficacy than interferon beta-1a on ARR and risk of new T2 lesions, with a good safety profile. Natalizumab tend to emerge as the most effective treatment.PMID:37245449 | DOI:10.1016/j.ejpn.2023.05.001 (Source: European Journal of Paediatric Neurology)
Source: European Journal of Paediatric Neurology - May 28, 2023 Category: Neurology Authors: Anne-Charlotte Saponaro Thomas Tully Elisabeth Maillart H élène Maurey Kumaran Deiva KidBiosep cohort study Source Type: research
Treatments of paediatric multiple sclerosis: Efficacy and tolerance in a longitudinal follow-up study
CONCLUSION: In this real-world setting, newer DMTs showed better efficacy than interferon beta-1a on ARR and risk of new T2 lesions, with a good safety profile. Natalizumab tend to emerge as the most effective treatment.PMID:37245449 | DOI:10.1016/j.ejpn.2023.05.001 (Source: European Journal of Paediatric Neurology)
Source: European Journal of Paediatric Neurology - May 28, 2023 Category: Neurology Authors: Anne-Charlotte Saponaro Thomas Tully Elisabeth Maillart H élène Maurey Kumaran Deiva KidBiosep cohort study Source Type: research
Treatments of paediatric multiple sclerosis: Efficacy and tolerance in a longitudinal follow-up study
CONCLUSION: In this real-world setting, newer DMTs showed better efficacy than interferon beta-1a on ARR and risk of new T2 lesions, with a good safety profile. Natalizumab tend to emerge as the most effective treatment.PMID:37245449 | DOI:10.1016/j.ejpn.2023.05.001 (Source: European Journal of Paediatric Neurology)
Source: European Journal of Paediatric Neurology - May 28, 2023 Category: Neurology Authors: Anne-Charlotte Saponaro Thomas Tully Elisabeth Maillart H élène Maurey Kumaran Deiva KidBiosep cohort study Source Type: research
Treatments of paediatric multiple sclerosis: Efficacy and tolerance in a longitudinal follow-up study
CONCLUSION: In this real-world setting, newer DMTs showed better efficacy than interferon beta-1a on ARR and risk of new T2 lesions, with a good safety profile. Natalizumab tend to emerge as the most effective treatment.PMID:37245449 | DOI:10.1016/j.ejpn.2023.05.001 (Source: European Journal of Paediatric Neurology)
Source: European Journal of Paediatric Neurology - May 28, 2023 Category: Neurology Authors: Anne-Charlotte Saponaro Thomas Tully Elisabeth Maillart H élène Maurey Kumaran Deiva KidBiosep cohort study Source Type: research
Treatments of paediatric multiple sclerosis: Efficacy and tolerance in a longitudinal follow-up study
CONCLUSION: In this real-world setting, newer DMTs showed better efficacy than interferon beta-1a on ARR and risk of new T2 lesions, with a good safety profile. Natalizumab tend to emerge as the most effective treatment.PMID:37245449 | DOI:10.1016/j.ejpn.2023.05.001 (Source: European Journal of Paediatric Neurology)
Source: European Journal of Paediatric Neurology - May 28, 2023 Category: Neurology Authors: Anne-Charlotte Saponaro Thomas Tully Elisabeth Maillart H élène Maurey Kumaran Deiva KidBiosep cohort study Source Type: research
Clinical and economic evaluations of natalizumab, rituximab, and ocrelizumab for the management of relapsing-remitting multiple sclerosis in Saudi Arabia
The advent of new disease-modifying therapies (DMTs), such as monoclonal antibodies (mAbs), resulted in significant changes in the treatment guidelines for Multiple sclerosis (MS) and improvement in the clinic... (Source: BMC Health Services Research)
Source: BMC Health Services Research - May 26, 2023 Category: General Medicine Authors: Mansour A. Alharbi, Fahad Aldosari, Ahmed Hasan Althobaiti, Faris M. Abdullah, Salman Aljarallah, Nuha M. Alkhawajah, Miteb Alanazi and Yazed AlRuthia Tags: Research Source Type: research
High levels of endothelial ICAM-1 prohibit natalizumab mediated abrogation of CD4+ T cell arrest on the inflamed BBB under flow in vitro
The humanized anti- α4 integrin blocking antibody natalizumab (NTZ) is an effective treatment for relapsing–remitting multiple sclerosis (RRMS) that is associated with the risk of progressive multifocal leukoen... (Source: Journal of Neuroinflammation)
Source: Journal of Neuroinflammation - May 23, 2023 Category: Neurology Authors: Sasha Soldati, Alexander B är, Mykhailo Vladymyrov, Dale Glavin, James L. McGrath, Fabien Gosselet, Hideaki Nishihara, Susan Goelz and Britta Engelhardt Tags: Research Source Type: research
A systematic review of the safety and efficacy of monoclonal antibodies for progressive multiple sclerosis
CONCLUSION: Based on our findings, Ocrelizumab is the most efficient monoclonal antibody for primary PMS, although it is associated with a higher risk of infection. While other monoclonal antibodies did not show significant promise in treating PMS, more research is necessary.PMID:37209514 | DOI:10.1016/j.intimp.2023.110266 (Source: International Immunopharmacology)
Source: International Immunopharmacology - May 20, 2023 Category: Allergy & Immunology Authors: Zahra Sabahi Amin Daei Sorkhabi Aila Sarkesh Amirreza Naseri Nazli Asghar-Rezaei Mahnaz Talebi Source Type: research
A systematic review of the safety and efficacy of monoclonal antibodies for progressive multiple sclerosis
CONCLUSION: Based on our findings, Ocrelizumab is the most efficient monoclonal antibody for primary PMS, although it is associated with a higher risk of infection. While other monoclonal antibodies did not show significant promise in treating PMS, more research is necessary.PMID:37209514 | DOI:10.1016/j.intimp.2023.110266 (Source: International Immunopharmacology)
Source: International Immunopharmacology - May 20, 2023 Category: Allergy & Immunology Authors: Zahra Sabahi Amin Daei Sorkhabi Aila Sarkesh Amirreza Naseri Nazli Asghar-Rezaei Mahnaz Talebi Source Type: research
Evaluation of risk management in a natalizumab home infusion procedure
Rev Neurol (Paris). 2023 May 16:S0035-3787(23)00943-8. doi: 10.1016/j.neurol.2023.01.727. Online ahead of print.ABSTRACTNatalizumab is a well-established disease-modifying therapy used in active multiple sclerosis (MS). The most serious adverse event is progressive multifocal leukoencephalopathy. For safety reasons, hospital implementation is mandatory. The SARS-CoV-2 pandemic has deeply affected hospital practices leading French authorities to temporarily authorize to administer the treatment at home. The safety of natalizumab home administration should be assessed to allow ongoing home infusion. The aim of the study is t...
Source: Revue Neurologique - May 18, 2023 Category: Neurology Authors: J-C Lafontaine J Boucher J Giovannelli J Petit O Outteryck S Balagny H Z éphir Source Type: research
Anti-GABA-A Receptor Antibody-Mediated Epilepsia Partialis Continua After Treatment With Alemtuzumab: A Case Report
We present a young woman with prediagnosis of relapse remitting multiple sclerosis (MS), treated with interferons, natalizumab, and alemtuzumab. Six months after one and only cycle of alemtuzumab, speech arrest and behavioral changes with aggressive and anxious traits appeared. She showed increasing motor convulsions resulting in focal status epilepticus.RESULTS: Anti-GABA-A receptor antibodies in CSF and serum were confirmed in different external laboratories, in a more extensive analysis after antibodies against NMDAR, CASPR2, LGI1, GABABR, and AMPAR were ruled out during in-house examination. Clinical condition improved...
Source: Herpes - May 18, 2023 Category: Infectious Diseases Authors: Dominica Ratuszny Thomas Skripuletz Thomas St über Emil Valizada Klaus Gehring Philipp Ertl J örg Andreas Müller Mike P Wattjes Friedrich Feuerhake Kurt-Wolfram S ühs Source Type: research
Evaluation of risk management in a natalizumab home infusion procedure
Rev Neurol (Paris). 2023 May 16:S0035-3787(23)00943-8. doi: 10.1016/j.neurol.2023.01.727. Online ahead of print.ABSTRACTNatalizumab is a well-established disease-modifying therapy used in active multiple sclerosis (MS). The most serious adverse event is progressive multifocal leukoencephalopathy. For safety reasons, hospital implementation is mandatory. The SARS-CoV-2 pandemic has deeply affected hospital practices leading French authorities to temporarily authorize to administer the treatment at home. The safety of natalizumab home administration should be assessed to allow ongoing home infusion. The aim of the study is t...
Source: Revue Neurologique - May 18, 2023 Category: Neurology Authors: J-C Lafontaine J Boucher J Giovannelli J Petit O Outteryck S Balagny H Z éphir Source Type: research
